{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:51:17Z","timestamp":1790117477050,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012869","name":"Morgan Adams Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jtct.2022.07.022","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T20:31:11Z","timestamp":1658781071000},"page":"694.e1-694.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax\u00a0+\u00a0Azacitidine Versus Intensive Chemotherapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-7505","authenticated-orcid":false,"given":"Amanda C.","family":"Winters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-2772","authenticated-orcid":false,"given":"Grace","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Minhajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-0716","authenticated-orcid":false,"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.07.022_bib0001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0002","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms","volume":"32","author":"Halpern","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.022_bib0003","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2022.07.022_bib0004","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0005","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.022_bib0006","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.022_bib0007","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2019.05.007","article-title":"Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: a systematic review and meta-analysis","volume":"82","author":"Stone","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.07.022_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2019.03.004","article-title":"Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients","volume":"80","author":"Hilberink","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2022.07.022_bib0011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.022_bib0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2022.07.022_bib0014","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","article-title":"Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia","volume":"26","author":"Sandhu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2022.07.022_bib0015","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/bjh.17996","article-title":"Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia","volume":"196","author":"Salhotra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0016","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1080\/10428194.2021.1966788","article-title":"Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant","volume":"62","author":"Bewersdorf","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.07.022_bib0017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2022.07.022_bib0018","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0019","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.022_bib0021","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ajh.24782","article-title":"Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia","volume":"92","author":"Ragon","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0022","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/bloodadvances.2020003195","article-title":"Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial","volume":"5","author":"Simoes","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.022_bib0023","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0024","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.022_bib0025","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.07.022_bib0027","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0028","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0029","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.07.022_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.15540","volume":"183","author":"Canaani","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","article-title":"The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts","volume":"54","author":"Liu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.022_bib0032","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0033","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0034","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.022_bib0035","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.022_bib0036","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jtct.2022.07.022_bib0037","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.07.022_bib0038","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2022.07.022_bib0039","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.1002\/ajh.26524","article-title":"Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia","volume":"97","author":"Kennedy","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.07.022_bib0040","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:41Z","timestamp":1763003201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722015093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2666636722015093"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax\u00a0+\u00a0Azacitidine Versus Intensive Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}